炭疽治療市場 - 類型（吸入、皮膚、胃腸道、注射）、藥物類別（抗生素、免疫球蛋白、聯合治療）、給藥途徑（腸胃外、口服）、配銷通路和預測（2024 - 2032）

Anthrax Treatment Market - Type (Inhalation, Cutaneous, Gastrointestinal, Injection), Drug Class (Antibiotics, Immunoglobulins, Combination Therapy), Route of Administration (Parenteral, Oral), Distribution Channel & Forecast (2024 - 2032)

出版日期: 2024年05月30日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

受炭疽發病率和風險增加的推動，全球炭疽治療市場在 2024 年至 2032 年間將以 7.9% 的複合年成長率成長，這與醫學研究的進步一致。由於炭疽爆發和生物恐怖主義威脅的可能性持續存在，對有效治療的需求不斷增加。此外，持續的研究和開發導致了創新療法的引入，增強了治療選擇。高風險和持續醫療進步的結合推動了市場擴張，確保提供新的有效解決方案來有效管理和治療炭疽感染。

例如，2023 年 7 月，美國食品藥物管理局 (FDA) 批准 Cyfendus 用於 18 至 65 歲接觸過炭疽的成年人。這項批准凸顯了新治療方案的進步，擴大了炭疽的治療範圍。它意味著對開發有效炭疽療法的投資增加，並強調了應對生物威脅的承諾。 Cyfendus 的推出可能會加強治療方案，促進市場成長，並有助於改善全球炭疽感染的管理。

炭疽治療產業根據類型、藥物類別、給藥途徑、配銷通路和地區進行分類。

到 2032 年，由於這種形式的炭疽相對於其他類型的炭疽的流行，皮膚炭疽市場將經歷顯著的改善。皮膚炭疽以皮膚損傷和潰瘍為特徵，是最常見、最容易識別的疾病形式，導致更高的治療需求。皮膚炭疽的有效管理涉及及時診斷和抗生素治療，從而推動了市場的重大關注。相對較高的發病率和簡單的治療選擇有助於該細分市場的主導市場地位。

免疫球蛋白部分在 2024 年至 2032 年間將大幅成長，因為它們在提供針對炭疽毒素的被動免疫方面發揮著至關重要的作用。免疫球蛋白，例如炭疽免疫球蛋白，對於透過中和毒素和防止疾病進展來治療嚴重炭疽病例至關重要。它們的有效性，特別是與抗生素結合使用，增加了它們的需求。作為綜合炭疽治療方案的關鍵組成部分，免疫球蛋白對於管理和減輕炭疽感染的影響至關重要，從而推動了其可觀的市場佔有率。

由於其完善的醫療基礎設施和先進的醫學研究能力，歐洲炭疽治療市場從 2024 年到 2032 年將出現顯著的複合年成長率。該地區健全的監管框架和積極主動的公共衛生策略有助於有效的炭疽管理。此外，歐洲國家對生物防禦和生物威脅防範的重視推動了對炭疽治療方案的大量投資。歐洲強大的醫療保健系統和研究計劃使其成為全球炭疽治療行業的主要貢獻者，在創新和實施方面處於領先地位。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Alembic Pharmaceuticals Limited
Almirall, LLC
Bayer AG
Emergent BioSolutions
GlaxoSmithKline plc
GC Biopharma, corp.
Integrated Bio Therapeutics Inc.
Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
Paratek Pharmaceuticals, Inc.
Pfizer Inc.
Porton Biopharma
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 9700

Global Anthrax Treatment Market will grow at a 7.9% CAGR between 2024 and 2032, propelled by the increasing incidence and risk of anthrax, in line with advancements in medical research. As the potential for anthrax outbreaks and bioterrorism threats persists, the demand for effective treatments rises. Also, ongoing research and development led to the introduction of innovative therapies, enhancing treatment options. This combination of heightened risk and continuous medical advancements propels market expansion, ensuring that new and effective solutions are available to manage and treat anthrax infections effectively.

For instance, in July 2023, the United States Food and Drug Administration (FDA) granted approval for Cyfendus to be used in adults aged 18 to 65 who have been exposed to anthrax. This approval highlights the advancement of new therapeutic options, expanding the range of treatments available for anthrax. It signifies increased investment in the development of effective anthrax therapies and underscores a commitment to addressing biological threats. The introduction of Cyfendus is likely to enhance treatment protocols, boost market growth, and contribute to improved management of anthrax infections globally.

The anthrax treatment industry is divided based on type, drug class, route of administration, distribution channel, and region.

The cutaneous anthrax segment will experience a marked upturn through 2032, driven by the prevalence of this form of anthrax compared to other types. Cutaneous anthrax, characterized by skin lesions and ulcers, is the most common and readily identified form of the disease, leading to higher treatment demand. Effective management of cutaneous anthrax involves prompt diagnosis and antibiotic therapy, driving significant market focus. The relatively higher incidence and straightforward treatment options contribute to this segment's dominant market position.

The immunoglobulins segment will witness a considerable surge between 2024 and 2032, attributed to their crucial role in providing passive immunity against anthrax toxins. Immunoglobulins, such as anthrax immune globulin, are essential in treating severe cases of anthrax by neutralizing toxins and preventing disease progression. Their effectiveness, particularly in combination with antibiotics, enhances their demand. As a key component of comprehensive anthrax treatment protocols, immunoglobulins are vital in managing and mitigating the impact of anthrax infections, driving their decent market share.

Europe anthrax treatment market will register a noteworthy CAGR from 2024 to 2032, owing to its well-established healthcare infrastructure and advanced medical research capabilities. The region's robust regulatory framework and proactive public health strategies contribute to effective anthrax management. Additionally, European countries' focus on biodefense and preparedness against biological threats drives substantial investment in anthrax treatment options. Europe's strong healthcare systems and research initiatives make it a major contributor to the global anthrax treatment industry, leading in both innovation and implementation.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for effective anthrax treatment
  - 3.2.1.2 Rising healthcare investments
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of awareness for diagnostic tests
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Inhalation anthrax
5.3 Cutaneous anthrax
5.4 Gastrointestinal anthrax
5.5 Injection anthrax

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Antibiotics
6.3 Immunoglobulins
6.4 Combination therapy

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Parenteral
7.3 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa